Bayer: Chinese health authority approves Verquvo

(CercleFinance.com) - Bayer reports that China's National Medical Products Administration (NMPA) has approved vericiguat under the brand name Verquvo (in 2.
5mg, 5mg and 10mg), for adults with chronic symptomatic heart failure and reduced ejection fraction (less than 45%).

This approval is an important milestone for heart failure patients across China, providing a new option to help break the cycle of worsening heart failure events and repeat hospitalisations, Bayer said.

The company says that Verquvo has been approved in the US, EU, Japan and many other countries worldwide and that several other applications for marketing authorisation are also underway.


Copyright (c) 2022 CercleFinance.com. All rights reserved.